NS34A resistance-associated substitutions in chronic hepatitis C in Upper Egypt and regression of liver fibrosis after direct-acting antiviral therapy

Egyptian Liver Journal

Table 4 Fibrosis stage before and 72 weeks after SMV/SOF therapy in SVR patients

Liver fibrosis stage	Before treatment (baseline)	72 weeks after treatment	P value
F0	10 (17.5%)	20 (35%)	0.001*
F1	4 (7%)	13 (22.9%)	0.001*
F2	17 (29.8%)	7 (12.3%)	0.001*
F3	10 (17.5%)	2 (3.5%)	0.001*
F4	16 (28.2%)	15 (26.3%)	ns